Abstract
Background: Both Bipolar Disorder (BD) and Obsessive Compulsive Disorder (OCD) are chronic psychiatric conditions, the first characterized by depressive and manic mood episodes and the latter characterized by obsessions and compulsions. The comorbidity between BD and OCD is not rare, and the presence of both conditions conveys important complications. The treatment supposes a challenge since antidepressants, first choice of treatment for OCD, carry an important risk for bipolar patients.
Objective: In the present review our aim was to find evidence on Quetiapine's efficacy in the treatment of bipolar disorder with comorbid OCD. Method: We performed a literature review on the treatment options for comorbid BD and OCD, Quetiapine’s use in OCD and anxiety disorders and finally a MEDLINE search about the use of Quetiapine for this specific indication.
Conclusion: The use of Quetiapine could be justified in patients with cycling OCD and in those who have shown benefit from this antipsychotic for BD and can tolerate adjunctive antidepressants. Still, clinical trials including this specific comorbid population should be performed to consider Quetiapine as part of BD-OCD patient’s treatment.
Keywords: Bipolar disorder, obsessive compulsive disorder, comorbid, treatment, antipsychotic, quetiapine, SSRI.
Current Psychopharmacology
Title:The Use of Quetiapine for Comorbid Bipolar and Obsessive Compulsive Disorders
Volume: 4
Author(s): María Yoldi-Negrete, Mónica Flores-Ramos, Alejandra Montserrat Rodríguez-Ramírez, Carvajal-Lohr Armando, Jorge Ávila-Solorio, Martin-Manzo María Alejandra, Andrade Alejandra and Leonardo González-Flores
Affiliation:
Keywords: Bipolar disorder, obsessive compulsive disorder, comorbid, treatment, antipsychotic, quetiapine, SSRI.
Abstract: Background: Both Bipolar Disorder (BD) and Obsessive Compulsive Disorder (OCD) are chronic psychiatric conditions, the first characterized by depressive and manic mood episodes and the latter characterized by obsessions and compulsions. The comorbidity between BD and OCD is not rare, and the presence of both conditions conveys important complications. The treatment supposes a challenge since antidepressants, first choice of treatment for OCD, carry an important risk for bipolar patients.
Objective: In the present review our aim was to find evidence on Quetiapine's efficacy in the treatment of bipolar disorder with comorbid OCD. Method: We performed a literature review on the treatment options for comorbid BD and OCD, Quetiapine’s use in OCD and anxiety disorders and finally a MEDLINE search about the use of Quetiapine for this specific indication.
Conclusion: The use of Quetiapine could be justified in patients with cycling OCD and in those who have shown benefit from this antipsychotic for BD and can tolerate adjunctive antidepressants. Still, clinical trials including this specific comorbid population should be performed to consider Quetiapine as part of BD-OCD patient’s treatment.
Export Options
About this article
Cite this article as:
Yoldi-Negrete María, Flores-Ramos Mónica, Rodríguez-Ramírez Alejandra Montserrat, Armando Carvajal-Lohr, Ávila-Solorio Jorge, María Alejandra Martin-Manzo, Alejandra Andrade and González-Flores Leonardo, The Use of Quetiapine for Comorbid Bipolar and Obsessive Compulsive Disorders, Current Psychopharmacology 2015; 4 (2) . https://dx.doi.org/10.2174/2211556005666151216224828
DOI https://dx.doi.org/10.2174/2211556005666151216224828 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
PD-1 Inhibitors in Neuroprotection: Modulating Neurotransmitter Pathways for Therapy
Programmed cell death protein-1 (PD-1) inhibitors, widely recognized for their role in immunotherapy, have recently emerged as potential neuroprotective agents. Beyond their traditional application in oncology, PD-1 inhibitors influence neuroimmune interactions, impacting neurotransmitter pathways critical for maintaining brain homeostasis. Dysregulation of these pathways is implicated in neurodegenerative and neuropsychiatric disorders, ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structural and Aggregation Properties of Alpha-Synuclein Linked to Phospholipase A2 Action
Protein & Peptide Letters Myocardial Energetics in Left Ventricular Hypertrophy
Current Cardiology Reviews Cell Immunity in Inflammatory Vasculitis
Current Immunology Reviews (Discontinued) Genetics of Anxiety Disorders - Status Quo and Quo Vadis
Current Pharmaceutical Design Interleukin-10 and Articular Cartilage: Experimental Therapeutical Approaches in Cartilage Disorders
Current Gene Therapy Adolescent Cannabis Use: What is the Evidence for Functional Brain Alteration?
Current Pharmaceutical Design Imino-Sugar-Based Nucleosides
Current Topics in Medicinal Chemistry Stem Cell Aging and Age-Related Cardiovascular Disease: Perspectives of Treatment by Ex-vivo Stem Cell Rejuvenation
Current Drug Targets Nano Strategies for Diagnosis and Treatment of Inflammatory Hyperalgesia
Current Nanomaterials Sleep and the Immune System
Current Immunology Reviews (Discontinued) Proline-Directed Protein Kinase FA as a Potential Target for Diagnosis and Therapy of Human Cancers
Current Cancer Drug Targets The Role of Genes Involved in Neuroplasticity and Neurogenesis in the Observation of a Gene-Environment Interaction (GxE) in Schizophrenia
Current Molecular Medicine Estrogen, Neuroprotection and Neurogenesis after Ischemic Stroke
Current Drug Targets Metabolic Stress and Inflammation: Implication in Treatment for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design Acute Kidney Injury, Hyperbilirubinemia, and Ischemic Skin Necrosis Due to Massive Sulindac Overdose
Current Drug Safety Modeling Neuronal Diseases in Zebrafish in the Era of CRISPR
Current Neuropharmacology ACE Inhibition, p300, Serum Nitrite and Lipid Peroxidation in Newly Diagnosed Hypertensives
Vascular Disease Prevention (Discontinued) Melatonin and Regulation of Immune Function: Impact on Numerous Diseases
Current Aging Science Meet Our Editorial Board Member
Current Neuropharmacology